医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mitsui Chemicals Purchases Share of DENTCA, Inc.

2013年06月21日 AM11:25
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

DENTCA's 3-Dimensional Denture (Photo: Business Wire)DENTCA’s 3-Dimensional Denture (Photo: Business Wire)

View and Share Photo

Close Window


TOKYO

Mitsui Chemicals, Inc. (TOKYO:4183), to further expand its dental material business, acquired 50.01% of issued and outstanding shares of DENTCA, Inc. (“DENTCA”) on June 20, 2013. DENTCA, with its head office in the United States, develops, manufactures, and distributes dentures using new cutting edge computer-aided design (CAD), computer aided manufacturing (CAM) technology, and proprietary 3-Dimensional modeling and printing technology.

DENTCA's 3-Dimensional Denture (Photo: Business Wire)

DENTCA’s 3-Dimensional Denture (Photo: Business Wire)

“Mitsui Chemicals, in line with one of its strategies in the FY2011 Mid-term Business Plan, has expanded its portfolio in businesses resilient to changing economic conditions such as healthcare,” stated Minoru Koshibe, Mitsui Chemicals Executive Vice President. “As part of this strategy, Mitsui Chemicals targets active expansion including M&As, such as this April’s acquisition of the dental materials business of German Heraeus Holdings GmbH, which has a global manufacturing and sales network.”

The dentures market is expected to continue to grow leveraged by the increase in aging of world-wide populations and rising incomes in emerging countries.

“We are pleased to become a partner of a well respected company like Mitsui Chemicals,” says Tae Hyung Kim, DENTCA President. “DENTCA and Mitsui Chemicals share a common philosophy that is, improving human life with innovative products.”

Mitsui Chemicals targets expansion of its global denture business through DENTCA’s cutting-edge denture design technology using CAD/CAM and its own advanced material development and processing technology to develop high-performance dentures that meet global needs. In addition, both parties will benefit from the synergistic effect brought by the abundant selection of dental-related materials of Heraeus Dental.

About Mitsui Chemicals

Mitsui Chemicals (TOKYO:4183)(ISIN:JP3888300005) contributes broadly to society by providing high-quality products and services to customers through innovations and creation of materials and products while keeping in harmony with the global environment. Mitsui Chemicals’ business portfolio includes petrochemicals, basic chemicals, polyurethanes, functional polymeric materials, functional chemicals, and films & sheets.

The Mitsui Chemicals Group traces its origins back to 1912. The Group now has over 100 companies and around 13,000 employees in over 10 countries worldwide. In the fiscal year ending March 2013, the Group posted consolidated sales of US$ 14,952 million.
More information can be found at http://www.mitsuichem.com/index.htm

About DENTCA

DENTCA, Inc. (Los Angeles, CA), the pioneer of CAD/CAM Denture Technology, produces high-quality dentures in just two visits through CAD/CAM, proprietary 3D modeling and printing technology. By introducing game-changing technology to dentistry, DENTCA received the Pride Institute’s Best-of-Class Technology Award in 2012 — the first denture company in history to receive this coveted award.

DENTCA’s patented tray system is designed to save significant time by enabling doctors to capture the impression, VD and CR in the same patient visit in less than one hour of chair time. With extensive patent protection, client relations, and dedication to R&D, DENTCA is committed to advancing modern dentistry with this state-of-the-art, revolutionary technology for years to come.
More information can be found at http://www.dentca.com/

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130620005532/en/

CONTACT

Mitsui Chemicals
Yuri Matsunaga, +81-3-6253-2100
Corporate
Communications Division
Yuuri.Matsunaga@mitsui-chem.co.jp
or
DENTCA
(Los Angeles, U.S.)
Younger Hong, +1-323-232-7505
info@dentca.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc